Outcomes of the Supris Sling in an Urban Latina Population.

Urology

Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Beverly Hills, CA. Electronic address:

Published: May 2022

Objective: To analyze patient reported outcomes, safety, and efficacy of the Supris mid-urethral sling in a diverse population.

Methods: A retrospective chart review of 101 women who underwent a mid-urethral Suprissling procedure was conducted. Baseline characteristics and perioperative parameters were collected. Post-operative results and patient reported outcomes were collected at an average follow-up time of 19 months using the Urogenital Distress Inventory-6 (UDI-6) and Patient Global Impression of Improvement (PGI-I) validated questionnaires. Subjective cure rates were compared using the nonparametric Wilcoxon Rank Sum Test.

Results: The median age of women was 57 years old, and 86.1% identified as Latina. 28% and 72% of women had a SUI and MUI diagnosis, respectively. Women, on average, used 2 pads pre-operatively and none post-operatively. There was a 3% surgical revision rate. 80 women completed the questionnaires. 82% of the MUI group reported being very much improved or much better. The SUI group reported being 94% very much improved or much better. The UDI-6 questions related to urgency and leakage of small amounts of urine were significantly different between the MUI and SUI groups (P = .002 and P = .044).

Conclusion: In our primarily Latina patient population, the majority of whom had MUI, the Supris retropubic sling greatly improved symptoms. Although reported outcomes were excellent in both groups, those with pre-operative urge incontinence were more likely to experience urge symptoms post-operatively. Despite persistent urge symptoms, patients reported improvement of their overall symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2021.07.054DOI Listing

Publication Analysis

Top Keywords

reported outcomes
12
patient reported
8
group reported
8
improved better
8
urge symptoms
8
reported
6
women
5
outcomes
4
outcomes supris
4
supris sling
4

Similar Publications

Study Design: Retrospective cohort study.

Objective: Evaluate the utility of Delirium Risk Assessment Score (DRAS), Delirium Risk Assessment Tool (DRAT), and Delirium Elderly At-Risk (DEAR) in patients undergoing posterior lumbar interbody fusions.

Background: Surgical interventions can place patients at risk for postoperative delirium (POD), an acute and often severe cognitive impairment associated with poor outcomes.

View Article and Find Full Text PDF

Study Design: Systematic review and meta analysis.

Objective: To assess the safety and efficacy of staged versus same-day spinal fusion surgeries in Adult spinal deformity (ASD).

Background: ASD surgeries are associated with high complication rates, ranging from 10% to 40%.

View Article and Find Full Text PDF

Study Design: Prospective cohort study.

Objective: This study aims to define Substantial Clinical Benefit (SCB) thresholds for PROMIS physical function (PF) and pain interference (PI) in lumbar or thoracolumbar spine surgery population.

Summary Of Background Data: Patient-reported outcome measures (PROMs) are widely used in spine surgery to assess treatment efficacy.

View Article and Find Full Text PDF

Ten-Year Trends in Last Known Well to Arrival Time in Acute Ischemic Stroke Patients: 2014 to 2023.

Stroke

January 2025

Northwell Health, New Hyde Park, NY (N.G.F., M.X.S., J.O.H., S.R.F., J.J.W., J.M.K., P.C.S.).

Background: Many national initiatives focus on promoting early hospital arrival of patients with acute ischemic stroke (AIS) because treatment effectiveness is time-dependent. However, several studies reported time-delays in hospital arrival, especially during the COVID-19 pandemic. Our purpose was to evaluate the 10-year trends in last known well to arrival (LKWA) time and assess disparities in patients with AIS.

View Article and Find Full Text PDF

AimsThe cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!